PNEUMONIA IN PATIENTS WITH BRONCHO-OBSTRUCTIVE DISEASES TREATED WITH INHALED GLUCOCORTICOSTEROIDS
https://doi.org/10.24884/1607-4181-2017-24-2-31-34
Abstract
Relevance. The use of inhaled glucocorticosteroids (IHCs) is one of the main basic treatment options forbroncho-obstructive diseases.
IHCs suppress chronic inflammation in the bronchial tree, but can be associated with the risk of pneumonia due to impairment of bronchus mucosal immunity and increased microbial colonization in the mucosa.
Aim. The aim of this study was to evaluate the incidence and risk factors of pneumonia during the IHCs therapy in patients with chronic obstructive pulmonary disease (COPD), bronchial asthma (BA), and with combination of COPD and asthma.
Materials and methods. The retrospective study included patients with confirmed COPD, BA and combined COPD and asthma. The endpoint of this analysis was the incidence of pneumonia. Potential additional risk factors (age, gender, smoking, diagnosis, duration of the disease) were analyzed.
Results. A total of 220 patients with broncho-obstructive pathology were included in the retrospective analysis. 184 patients received IHCs. 34 patients obtaining the basic therapy with IHCs developed pneumonia with a cumulative incidence of 36 % after 10 years. The primary diagnosis, gender, age and smoking did not significantly impact the risk of pneumonia.
Conclusions. IHCs therapy is associated with a risk of pneumonia, which should be taken into account when planning long-term control of broncho-obstructive pathology.
About the Authors
E. A. Kulagin
Federal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russian Federation
Russian Federation
Competing Interests: конфликты интересов отсутствуют
Russian Federation
resident physician
6-8 L’va Tolstogo street, Saint-Petersburg, Russia, 197022
Competing Interests: конфликты интересов отсутствуют
V. I. Trofimov
Federal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russian Federation
Russian Federation
Competing Interests: конфликты интересов отсутствуют
Russian Federation
Prof., Dr. Sci. (Med.)
Competing Interests: конфликты интересов отсутствуют
References
1. Knyazheskaya NP, Chuchalin AG. Inhaled glucocorticosteroids (IHCs) – basis of anti-inflammatory treatment for bronchial astma.Efficiency, safety and applications of Pulmicort suspension (budesonide).Russian Medical Journal. 2008; (22): 1515. (in Russian)
2. Chuchalin AG. Pulmonology. National guidelines. Moscow: GEOTAR-Media. 2012; 306-322, 343-359. (in Russian)
3. Vogelmeier CF., Creaner GJ, Martinez FJ et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2016 Report. Global initiative for Chronic Obstructive Lung Disease (GOLD). 2016. URL: http://goldcopd.org/global-strategy-diagnosis-managementprevention-copd-2016/.
4. Vogelmeier CF, Creaner GJ, Martinez FJ et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. Global initiative for Chronic Obstructive Lung Disease (GOLD). 2017. URL: http://goldcopd.org/gold-2017-global-strategy-diagnosismanagement-prevention-copd/.
5. Dvoretskii LI, Sergeeva EV. The place of glucocorticosteroids in the treatment of patients with COPD. Russian Medical Journal. 2008; (7); 466. (in Russian)
6. Dvotetskii LI. Community-acquired pneumonia in patients with chronic obstructive lung disease. Practical Pulmonology. 2015. (2): URL: http://cyberleninka.ru/article/n/vnebolnichnaya-pnevmoniya-u-bolnyh-hronicheskoy- obstruktivnoy-boleznyu-legkih. (in Russian)
7. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease //New England Journal of Medicine. 2007. Vol. 356. №. 8. P. 775–789.
8. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. // Am J RespirCrit Care Med. 2007. № 176. P. 162–166.
Supplementary files
|
|
1. Неозаглавлен | |
| Subject | ||
| Type | Other | |
View
(1MB)
|
Indexing metadata ▾ | |
|
|
2. Неозаглавлен | |
| Subject | ||
| Type | Other | |
View
(91KB)
|
Indexing metadata ▾ | |
|
3. Неозаглавлен | |
| Subject | ||
| Type | Other | |
Download
(88KB)
|
Indexing metadata ▾ | |
|
|
4. Неозаглавлен | |
| Subject | ||
| Type | Other | |
Download
(102KB)
|
Indexing metadata ▾ | |
|
5. Неозаглавлен | |
| Subject | ||
| Type | Other | |
Download
(14KB)
|
Indexing metadata ▾ | |
|
|
6. Неозаглавлен | |
| Subject | ||
| Type | Other | |
Download
(15KB)
|
Indexing metadata ▾ | |
Review
For citations:
Kulagin E.A., Trofimov V.I. PNEUMONIA IN PATIENTS WITH BRONCHO-OBSTRUCTIVE DISEASES TREATED WITH INHALED GLUCOCORTICOSTEROIDS. The Scientific Notes of the Pavlov University. 2017;24(2):31-34. (In Russ.) https://doi.org/10.24884/1607-4181-2017-24-2-31-34
Views:
2306
Email this article 